Trial Outcomes & Findings for Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) (NCT NCT06357975)

Last Updated: 2026-03-19

Results Overview

ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Details about how to define complete response and partial response can be found in the master protocol. 90% two-sided binomial exact confidence interval is calculated for ORR.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE2

Target enrollment

44 participants

Primary outcome timeframe

Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Results posted on

2026-03-19

Participant Flow

Subprotocol C1 was activated on May 31, 2016. Forty-four patients were enrolled on EAY131-C1 between July 29, 2016, and November 12, 2021. Thirteen patients were enrolled on the basis of the results from the NCI-MATCH assay and 31 on the basis of the outside assay results.

For subprotocol C1, patients were required to have MET amplification defined as ≥7 copies/cell as identified by the Oncomine® Assay, or the Oncomine® Assay equivalent of 7 or greater as identified by a Designated Laboratory.

Participant milestones

Participant milestones
Measure	Treatment (Crizotinib) Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Overall Study STARTED	44
Overall Study Started Protocol Therapy	40
Overall Study Eligible, Treated and Mutation Status Confirmed	28
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	44

Reasons for withdrawal

Reasons for withdrawal
Measure	Treatment (Crizotinib) Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Overall Study Ineligible or Never Started	4
Overall Study Mutation Status Not Confirmed	12
Overall Study Adverse Event	4
Overall Study Disease Progression	19
Overall Study Other Complicating Disease	3
Overall Study Physician Decision	1
Overall Study On Treatment	1

Baseline Characteristics

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Treatment (Crizotinib) n=28 Participants Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Age, Continuous	67 years n=110 Participants
Sex: Female, Male Female	9 Participants n=110 Participants
Sex: Female, Male Male	19 Participants n=110 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=110 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	26 Participants n=110 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	2 Participants n=110 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=110 Participants
Race (NIH/OMB) Asian	0 Participants n=110 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=110 Participants
Race (NIH/OMB) Black or African American	3 Participants n=110 Participants
Race (NIH/OMB) White	23 Participants n=110 Participants
Race (NIH/OMB) More than one race	0 Participants n=110 Participants
Race (NIH/OMB) Unknown or Not Reported	2 Participants n=110 Participants

PRIMARY outcome

Timeframe: Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Population: Eligible, treated and mutation status confirmed

Outcome measures

Outcome measures
Measure	Treatment (Crizotinib) n=28 Participants Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Objective Response Rate (ORR)	14 percentage of participants Interval 5.0 to 29.8

SECONDARY outcome

Timeframe: Assessed at baseline, then every 2 cycles for the first 26 cycles, and every 3 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined

Population: Eligible, treated and mutation status confirmed

Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.

Outcome measures

Outcome measures
Measure	Treatment (Crizotinib) n=28 Participants Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
6-month Progression Free Survival (PFS)	14.3 percentage of participants Interval 5.6 to 26.8

SECONDARY outcome

Timeframe: Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Population: Eligible, treated and mutation status confirmed

PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.

Outcome measures

Outcome measures
Measure	Treatment (Crizotinib) n=28 Participants Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Progression Free Survival	3.4 months Interval 1.8 to 3.7

Adverse Events

Treatment (Crizotinib)

Serious events: 14 serious events

Other events: 33 other events

Deaths: 36 deaths

Serious adverse events

Serious adverse events
Measure	Treatment (Crizotinib) n=40 participants at risk Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Blood and lymphatic system disorders Anemia	7.5% 3/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Cardiac disorders Sinus bradycardia	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
General disorders and administration site conditions Fatigue	10.0% 4/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Gastrointestinal disorders Diarrhea	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Gastrointestinal disorders Nausea	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Gastrointestinal disorders Vomiting	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Infections and infestations Bone infection	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Infections and infestations Bronchial infection	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Infections and infestations Lung infection	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Infections and infestations Sepsis	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Infections and infestations Urinary tract infection	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Infections and infestations Infections and infestations - Other, specify	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Alanine aminotransferase increased	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Alkaline phosphatase increased	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Aspartate aminotransferase increased	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Lymphocyte count decreased	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Metabolism and nutrition disorders Dehydration	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Metabolism and nutrition disorders Hyponatremia	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Musculoskeletal and connective tissue disorders Neck pain	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Nervous system disorders Dizziness	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasms benign, malignant and unspecified (incl cysts and polyps) -	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Eye disorders Blurred vision	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Respiratory, thoracic and mediastinal disorders Dyspnea	2.5% 1/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Vascular disorders Hypotension	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).

Other adverse events

Other adverse events
Measure	Treatment (Crizotinib) n=40 participants at risk Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Blood and lymphatic system disorders Anemia	25.0% 10/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Cardiac disorders Sinus bradycardia	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
General disorders and administration site conditions Edema limbs	20.0% 8/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
General disorders and administration site conditions Fatigue	20.0% 8/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Skin and subcutaneous tissue disorders Rash acneiform	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Gastrointestinal disorders Abdominal pain	7.5% 3/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Gastrointestinal disorders Constipation	22.5% 9/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Gastrointestinal disorders Diarrhea	30.0% 12/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Gastrointestinal disorders Dyspepsia	12.5% 5/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Gastrointestinal disorders Gastroesophageal reflux disease	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Gastrointestinal disorders Nausea	30.0% 12/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Gastrointestinal disorders Vomiting	17.5% 7/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Infections and infestations Upper respiratory infection	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Alanine aminotransferase increased	12.5% 5/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Alkaline phosphatase increased	22.5% 9/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Aspartate aminotransferase increased	17.5% 7/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Creatinine increased	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Lymphocyte count decreased	22.5% 9/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Weight loss	7.5% 3/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations White blood cell decreased	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Investigations Investigations - Other, specify	7.5% 3/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Metabolism and nutrition disorders Anorexia	12.5% 5/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Metabolism and nutrition disorders Hyperglycemia	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Metabolism and nutrition disorders Hypoalbuminemia	17.5% 7/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Metabolism and nutrition disorders Hypocalcemia	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Metabolism and nutrition disorders Hyponatremia	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Nervous system disorders Dizziness	10.0% 4/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Nervous system disorders Dysgeusia	7.5% 3/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Nervous system disorders Headache	10.0% 4/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Eye disorders Blurred vision	7.5% 3/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Eye disorders Flashing lights	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Eye disorders Floaters	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Eye disorders Eye disorders - Other, specify	10.0% 4/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).
Respiratory, thoracic and mediastinal disorders Dyspnea	5.0% 2/40 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Forty patients were included in the toxicity analysis (excluding four who did not receive treatment).

Additional Information

Study Statistician

ECOG-ACRIN Cancer Research Group

Phone: 617-632-3012

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: LTE60